Alnylam Pharmaceuticals, Inc. (ALNY) Stock AnalysisALNYStock AnalysisAlnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alnylam Pharmaceuticals Inc is currently a hold. The stock is trading at $237.10, which is above the Fibonacci Pivot level of $233.68, indicating some short-term support. However, the stock has seen a significant decline of 40.75% year-to-date and 46.96% over the past year, raising concerns about its stability. The RSI is at 54.77, suggesting it is neither overbought nor oversold, which aligns with a cautious approach. The forward P/E ratio is 27.55, indicating that the stock is relatively expensive compared to its expected earnings growth. Analyst ratings vary, with a price target range from $230 to $455, showing mixed sentiment. The main risk is the recent negative trial results impacting its ATTR drug business, which could further pressure the stock.

18 analysts cover ALNY: 13 rate it Buy, 4 Hold and 1 Sell. The average price target is 479.53.